Skip to main content

Table 3 Clinical and biological variables before and after MARS® therapy in each group

From: Adverse events, short- and long-term outcomes of extra corporeal liver therapy in the intensive care unit: 16 years experience with MARS® in a single center

 

Acute-on-chronic liver failure

Acute liver failure

Post-surgery liver failure

Refractory pruritus

Drug intoxication

(n = 56)

(n = 32)

(n = 28)

(n = 52)

(n = 12)

Before MARS®

After MARS®

p value

Before MARS®

After MARS®

p value

Before MARS®

After MARS®

p value

Before MARS®

After MARS®

p value

Before MARS®

After MARS®

p value

Total bilirubin (µmol/L)

505 [311–642]

349 [228–403]

 < 0.01

341 [188–520]

268 [109–353]

 < 0.01

479 [337–551]

287 [176–347]

 < 0.01

82 [27–185]

62 [23–142]

 < 0.01

20 [11–112]

15 [11–61]

0.01

ALT (IU/L)

56 [34–117]

76 [43–175]

0.06

440 [121–1705]

250 [94–650]

 < 0.01

153 [81–241]

100 [60–150]

0.02

71 [43–90]

50 [33–94]

0.07

96 [33–202]

88 [21–130]

0.67

AST (IU/L)

102 [63–173]

128 [62–209]

0.03

259 [124–696]

116 [82–234]

0.02

100 [61–174]

72 [50–101]

0.04

73 [55–120]

67 [49–110]

0.07

60 [36–102]

49 [24–148]

0.72

GGT (IU/L)

67 [35–205]

92 [33–232]

0.45

131 [41–314]

115 [56–307]

0.48

143 [81–260]

134 [93–297]

0.96

155 [89–421]

148 [68–385]

 < 0.01

165 [69–253]

152 [48–242]

0.72

Prothrombin time (%)

42 [30–51]

47 [38–68]

 < 0.01

39 [19–52]

60 [39–74]

 < 0.01

61 [48–73]

63 [52–75]

0.56

90 [72–100]

82 [70–100]

0.64

78 [65–83]

78 [56–87]

0.76

Albumin (g/L)

33 [28–36]

31 [28–34]

0.20

30 [27–31]

31 [27–34]

0.12

30 [26–35]

30 [25–32]

0.34

33 [29–35]

33 [28–35]

0.11

28 [26–30]

29 [26–30]

0.96

Hemoglobin (g/dL)

9.0 [8.2–9.9]

9.4 [8.0–10.2]

0.83

10.7 [9.6–12.4]

9.5 [8.6–10.6]

 < 0.01

9.2 [8.6–10.2]

9.2 [8.2–8.6]

0.14

11.0 [9.7–11.8]

9.6 [9.0–10.6]

 < 0.01

9.2 [8.7–11.0]

9.3 [8.8–9.7]

0.13

Platelets count (× 109/L)

80 [57–116]

72 [54–101]

0.01

97 [70–159]

94 [66–132]

0.19

92 [63–104]

77 [53–88]

0.15

167 [106–236]

116 [75–168]

 < 0.01

116 [75–186]

163 [91–246]

0.97

Blood lactate concentration (mmol/L)

1.6 [1.2–2.1]

1.4 [1.0–1.8]

0.13

2.3 [1.7–2.8]

1.6 [1.2–2.5]

0.01

1.5 [1.2–2.2]

1.2 [1.3–1.8]

0.45

0.9 [0.7–1.4]

1.0 [0.9–1.4]

0.51

1.6 [1.2–2.3]

1.5 [1.0–1.9]

0.47

Glasgow coma scale score

14 [7–15]

15 [14, 15]

0.01

13 [4–15]

15 [11–15]

0.09

15 [9–15]

15 [9–15]

0.90

15 [15]

15 [15]

0.99

4 [3, 4]

15 [14, 15]

0.01

Encephalopathy (West Haven criteria)

2 [0–4]

1 [0–3]

0.01

2 [0–4]

0 [0–2]

0.01

1 [0–4]

1 [0–4]

0.99

0 [0–0]

0 [0–0]

0.99

NA

NA

 
  1. Continuous variables are presented as median with interquartile ranges [IQR]. Quantitative paired variables “Before” and “After” MARS® were compared using a paired Student t-test or Wilcoxon signed-rank test when appropriate (failure of normality test)
  2. ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma glutamyl transferase
  3. Bold indicates p value < 0.05 was considered statistically significant
Back to article page

Critical Care

ISSN: 1364-8535